N/A N=208 Conservative Treatment of Postprostatectomy Incontinence
Urinary Incontinence
Primary: Percent Change in Incontinence Episodes on Bladder Diary — 55; 51; 24 % change in episodes per week — p=.001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=27 Trastuzumab and Erlotinib as First-Line Therapy in Treating Women With Metastatic Breast Cancer Associated With HER2/Neu Overexpression
Breast Cancer
Primary: The Objective Response Rate as Defined as Stable Disease or the Rate of Complete and Partial Responses Determined on Two Consecutive Occasions Greater Than or Equal to 4…
N/A N=50 Comparing the Laryngoscopy View Using Miller and Macintosh Laryngoscopy Blades in Infants Under Two Years of Age
Percent of Glottic Opening
Primary: The View of the Larynx (Glottis Opening) as Determined by POGO Score (Percentage of Glottic Opening). — 84; 78 percentage of Glottic opening — p=>0.05
N/A N=309 Hepatitis C Translating Initiatives for Depression Into Effective Solutions
Hepatitis C · Depression
Primary: Number of Patients Who Initiated Hepatitis C Antiviral Treatment Within 12 Months of Enrollment — 11; 7 participants
Phase 4 N=64 Syphilis Response to Higher Penicillin Dosage: The 2.4 Versus 7.2 Study
Syphilis
Primary: Treatment Success Defined as a Decrease in Rapid Plasma Reagin (RPR) Titer of >= 2 Dilutions (4-fold) — 27; 28 participants
Phase 2 N=44 Lenalidomide With or Without Rituximab After Standard Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma
Lymphoma
Primary: Disease-free Survival at 1 Year — 0.818; 0.90 years
Early Phase 1 N=25 Trigeminal Nerve Stimulation for Attention Deficit Hyperactivity Disorder (ADHD)
Attention-Deficit/Hyperactivity Disorder
Primary: ADHD-IV Rating Scale (ADHD-RS) — 32.6 units on a scale
Phase 2 N=153 D/C/F/TAF Versus COBI-boosted DRV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment Naive Adults
Acquired Immunodeficiency Syndrome · HIV Infections
Primary: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24 — 74.8; 74.0 percentage of participants — p=0.64
Phase 4 N=61 Evaluate Effects and Safety of Pre-load Myfortic® in Transplant Patients
Kidney Transplant Recipients
Primary: Incidence of Biopsy-confirmed Acute Rejection by Banff '97 Criteria (Updated 2007) 3, 6 and 12 Months Post Transplant — 7; 3; 7; 3 participants
Phase 2 N=21 SOFIA-LTT Study: A Study of Intermittent Long Term Treatment With PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With HBeAg Negative Chronic Hepatitis B (CHB).
Hepatitis B, Chronic
Primary: Percentage of Participants With Stable Virological Response — 100; 100.0; 52.9; 66.7 Percentage of Participants
Phase 3 N=320 Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 Diabetes
Type 2 Diabetes
Primary: Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24 — -0.82; -0.1 Percentage of glycosylated hemoglobin — p=<0.0001
N/A N=80 Lidocaine Analgesia for Urethral Catheterization in Children
Pediatric Presentation of Urinary Tract Infection
Primary: Pain Score on the Face, Legs, Arms, Cry, Consolability (FLACC) Scale — 9; 8 units on a scale
Phase 3 N=81 TNF-alpha Antagonists for AECOPD: A Randomized, Double-Blind, Placebo-Controlled Pilot Trial
COPD Exacerbation
Primary: Change in Lung Function (Forced Expiratory Volume in 1 Second (FEV1) — 15.2; 20.1 percentage of change in FEV1
Phase 3 N=212 Safety and Efficacy Study of Topography-Guided LASIK to Treat Myopia and Hyperopia
Myopia · Hyperopia
Primary: Percentage of Eyes With Manifest Refraction Spherical Equivalent (MRSE) +/- 0.50 D — 94.78 Percentage of Eyes
Phase 3 N=136 Efficacy of Morning-only Bowel Preparation for Afternoon Colonoscopy.
Colon Cancer
Primary: Comparing All Morning Bowel Prep to Evening Bowel Prep for Patients Undergoing Afternoon Colonoscopies. (Using Ottawa Scale Scores, Range 0-14) Lower Score Indicates a…